REC-7735 in Participants With Solid Tumors

Part of paid clinical trials in Grand Rapids, Michigan.

Sponsor
Recursion Pharmaceuticals Inc.
Study ID
NCT07819136
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • REC-7735 — DRUG
    Oral

Study Details

The study is designed to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of REC-7735 in participants with unresectable, locally advanced, or metastatic PIK3CA-H1047R mutated solid tumors.

Key Dates

First listed
Sep 14, 2026
Start date
Sep 30, 2026
Status verified
Sep 2026
Primary completion
Jan 31, 2031
Completion
Jan 31, 2031

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1A Dose Finding: REC-7735
    Participants will receive REC-7735 twice daily (BID).
  • Experimental: Phase 1B Dose Expansion/Optimization: REC-7735
    Participants will receive REC-7735 BID.

Primary Outcome Measure

Phase 1A: Number of Participants With Dose-limiting Toxicities (DLTs) [ Time Frame: 28 days ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
START MidwestGrand RapidsMichigan49546
Hope Team Distribution List
[email protected]
NEXT Oncology - DallasIrvingTexas75039
Clinical Trial Navigator
[email protected]
972-893-8800
NEXT VirginiaFairfaxVirginia22031
Referral Coordinator
[email protected]
703-783-4518

Find similar trials in Grand Rapids, MI

By research site
START Midwest· Grand Rapids, MINEXT Oncology - Dallas· Irving, TXNEXT Virginia· Fairfax, VA

Related Studies